Perspective Therapeutics (NYSE:CATX) Receives “Outperform” Rating from Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating restated by Wedbush in a research note issued to investors on Monday,RTT News reports. They currently have a $11.00 target price on the stock. Wedbush’s price objective points to a potential upside of 223.53% from the company’s current price.

Several other analysts have also recently weighed in on the stock. Royal Bank of Canada dropped their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday, November 25th. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $24.00 to $5.00 in a report on Monday, November 25th. UBS Group started coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Truist Financial assumed coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Stock Performance

Shares of NYSE CATX traded down $0.10 during mid-day trading on Monday, reaching $3.40. 1,259,855 shares of the company were exchanged, compared to its average volume of 1,114,865. The company’s 50-day simple moving average is $5.16 and its 200-day simple moving average is $10.25. Perspective Therapeutics has a twelve month low of $2.70 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Johan M. Spoor acquired 8,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was bought at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. The trade was a 28.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Heidi Henson bought 25,975 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the purchase, the director now directly owns 25,975 shares of the company’s stock, valued at $100,003.75. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 67,570 shares of company stock worth $256,789 over the last quarter. 3.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CATX. Charles Schwab Investment Management Inc. boosted its holdings in Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after acquiring an additional 298,778 shares in the last quarter. WealthPlan Investment Management LLC purchased a new position in shares of Perspective Therapeutics in the 3rd quarter worth about $4,530,000. State Street Corp raised its position in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Hills Bank & Trust Co purchased a new position in Perspective Therapeutics in the 3rd quarter worth about $13,722,000. Finally, Janus Henderson Group PLC raised its position in Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after buying an additional 355,685 shares during the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.